WVE

Wave Life SciencesD

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$13.50

+137.3% vs current

Most likely

Base case

45%

Probability

Target price

$6.80

+19.5% vs current

B-

Bear case

30%

Probability

Target price

$3.80

-33.2% vs current

AI sentiment snapshot

Latest data as of 2026-04-15

AI commentary

This remains a cautious monitoring name, not a clean recovery setup. The evidence quality is decent because Wave has multiple primary-company disclosures, but catalyst density is still modest and the deterministic prior is negative. The March 26 WVE-007 update provided enough support to keep the obesity program alive, yet not enough to undo the credibility hit from the selloff; nearer-term upside now depends more on WVE-006 execution and on Wave proving that the next obesity study design can generate more convincing efficacy signals.

RankAlpha Sentiment Codex - 2026-04-15

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-05-18eventWVE-006 ATS late-breaking data on May 18, 2026 [#PR-2026-03-05]High impact

Wave said RestorAATion-2 data from the 400 mg multidose cohort and 600 mg single-dose cohort will be presented at ATS on May 18, 2026, with regulatory feedback on a potential accelerated approval pathway still expected mid-2026. A clean update would help shift focus away from the March obesity drawdown and back toward the RNA-editing franchise. [#PR-2026-03-05]

2026-06-30eventWVE-007 Phase 2a INLIGHT initiation in 2Q 2026 [#PR-2026-03-26]High impact

After the March 26 Phase 1 update, Wave said it is on track to start the multidose Phase 2a portion of INLIGHT in higher-BMI patients with comorbidities in 2Q 2026. Hitting that start matters because the Phase 1 signal did not produce enough near-term conviction on weight-loss magnitude by itself. [#PR-2026-03-26]

2026-09-30catalystAdditional WVE-007 data and new obesity study starts in 2026 [#PR-2026-03-26]High impact

Wave guided to additional INLIGHT data, including the 600 mg SAD cohort, and to new 2026 studies evaluating WVE-007 as an incretin add-on and post-incretin maintenance. These are the real forward hooks for repairing the obesity thesis after the March reset, but they remain development-stage and not yet well de-risked. [#PR-2026-03-26]

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-04-15 • Updated nightlySource: Internal modelMethodology